Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2009-07-14
2010-06-08
Yaen, Christopher H (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
Reexamination Certificate
active
07732144
ABSTRACT:
The present invention relates to prognostic methods which are useful in medicine, particularly cancer chemotherapy. The object of the invention to provide a method for assessing TS and/or ERCC1 expression levels in fixed or fixed and paraffin embedded tissues and prognosticate the probable resistance of a patient's tumor to treatment with 5-FU and oxaliplatin-based therapies by examination of the amount of TS and/or ERCC1 mRNA in a patient's tumor cells and comparing it to a predetermined threshold expression level for those genes. More specifically, the invention provides to oligonucleotide primer pairs ERCC1 and TS and methods comprising their use for detecting levels of ERCC1 and TS mRNA, respectively.
REFERENCES:
patent: 4830969 (1989-05-01), Holmes
patent: 4843155 (1989-06-01), Chomczynski
patent: 5128247 (1992-07-01), Koller
patent: 5284940 (1994-02-01), Lin et al.
patent: 5346994 (1994-09-01), Chomczynski
patent: 5502166 (1996-03-01), Mishina
patent: 5620852 (1997-04-01), Lin et al.
patent: 5637687 (1997-06-01), Wiggins
patent: 5643767 (1997-07-01), Fischetti et al.
patent: 5654179 (1997-08-01), Lin
patent: 5672696 (1997-09-01), Wang et al.
patent: 5705336 (1998-01-01), Reed et al.
patent: 5707802 (1998-01-01), Sandhu et al.
patent: 5728822 (1998-03-01), Macfarlane
patent: 5777099 (1998-07-01), Mehra
patent: 5945515 (1999-08-01), Chomczynski
patent: 5952202 (1999-09-01), Aoyagi et al.
patent: 5989857 (1999-11-01), Mundschenk
patent: 5998151 (1999-12-01), Johnston et al.
patent: 6010700 (2000-01-01), Richt
patent: 6043354 (2000-03-01), Hillebrand et al.
patent: 6204375 (2001-03-01), Lader
patent: 6207408 (2001-03-01), Essenfeld et al.
patent: 6248535 (2001-06-01), Danenberg et al.
patent: 6518416 (2003-02-01), Danenberg
patent: 6613518 (2003-09-01), Danenberg et al.
patent: 7049059 (2006-05-01), Danenberg
patent: 2002/0090642 (2002-07-01), Johnston et al.
patent: 1 420 927 (2003-05-01), None
patent: 0 290 144 (1988-09-01), None
patent: 2003-525033 (2003-08-01), None
patent: WO 90/02203 (1990-03-01), None
patent: WO 95/28489 (1995-10-01), None
patent: WO 97/05248 (1997-02-01), None
patent: WO 97/35034 (1997-09-01), None
patent: WO 98/41648 (1998-09-01), None
patent: WO 01/46402 (2001-06-01), None
Ardalan, B., et al., “Thymidylate Synthase Gene Expression in Normal and Malignant Colorectal Tissues: Relation to in vivo Response and Survival,” Proceedings of the American Association for Cancer Research, vol. 37, Abstract No. 1376 (Mar. 1996).
Aschele, C., et al., “Thymidylate Synthase Protein Expression in Primary Colorectal Cancer Compared with the Corresponding Distant Metastases and Relationship with the Clinical Response to 5-Fluorouracil,” Clinical Cancer Research, 6: 4797-4802 (2000).
Ausubel, F.M., ed.,Current Protocols In Molecular Biology, John Wiley & Sons, Inc., vol. 1.; Strauss, W. M., “Preparation of Genomic DNA from Mammalian Tissue,” Unit 2.2, pp. 2.2.1-2.2.3 (1998).
Ausubel, F.M., ed.,Current Protocols In Molecular Biology, John Wiley & Sons, Inc., vol. 1.; Richards, E., et al., “Preparation of Genomic DNA from Plant Tissue,” Unit 2.3, pp. 2.3.1-2.3.7 (1994).
Ausubel, F.M., ed.,Current Protocols In Molecular Biology, John Wiley & Sons, Inc., vol. 1.; Wilson, K., “Preparation of Genomic DNA from Bacteria,” Unit 2.4, pp. 2.4.1-2.4.5 (1994).
Banerjee, S.K., et al., “Microwave-Based DNA Extraction from Paraffin-Embedded Tissue for PCR Amplification,” BioTechniques, vol. 18, No. 5, pp. 768, 770, 772, 773 (1995).
Beck, A., et al., “A Role for Dihydropyrimidine Dehydrogenase and Thymidylate Synthase in Tumour Sensitivity to Fluorouracil,” European Journal of Cancer, 30A(10):1517-1522 (1994).
Benhattar, J., et al., “p53 Mutations as a Possible Predictor of Response to Chemotherapy in Metastatic Colorectal Carcinomas,” Int. J. Cancer (Pred. Oncol.), vol. 69, pp. 190-192 (1996).
Britten, et al., “ERCC1 Expression as a Molecular Marker of Cisplatin Resistance in Human Cervical Tumor Cells,” Int. J. Cancer 89(5): pp. 453-457 (2000).
Bresters, D., et al., “Detection of Hepatitis C Viral RNA Sequences in Fresh and Paraffin-Embedded Liver Biopsy Specimens of Non-A, Non-B Hepatitis Patients,” J. Hepat., vol. 15, pp. 391-395 (1992).
Bresters, D., et al., “The Duration of Fixation Influences the Yield of HCV cDNA-PCR Products from Formalin-Fixed, Paraffin-Embedded Liver Tissue,” J. Virol. Method, vol. 48, pp. 267-272 (1994).
Chen, Z., et al., “Correlation of Cisplatin Sensitivity with Differential Alteration of EGFR Expression in Head and Neck Cancer Cells,” Anticancer Research 20:899-902 (2000).
Chirgwin, J., M., et al., “Isolation of Biologically Active Ribonucleic Acid from Sources Enriched in Ribonuclease,” Biochemistry, vol. 18, No. 24, pp. 5294-5299 (1979).
Chomczynski, P., et al., “Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate-Phenol-Chloroform Extraction,” Analytical Biochemistry, vol. 162, pp. 156-159 (1987).
Chomczynski, P., “A Reagent for the Single-Step Simultaneous Isolation of RNA, DNA and Proteins from Cell and Tissue Samples,” BioTechniques, vol. 15, No. 3, pp. 532-534, 536-537 (1993).
Codegoni, et al., “Expression of Genes of Potential Importance in the Response to Chemotherapy and DNA Repair in Patients with Ovarian Cancer,” Gynecol Oncol., Apr.; 65(1): 130-7 (1997).
Coombs, N. J., et al., “Optimisation of DNA and RNA Extraction from Archival Formalin-Fixed Tissue,” Nucl. Acids Research, vol. 27, No. 16, pp. i-iii (1999).
Dabholkar, et al., “Expression of Excision Repair Genes in Non-malignant Bone Marrow from Cancer Patients,” Mutat Res., Jan.; 293(2): 151-60 (1993).
Dabholkar, et al., “ERCC1 and ERCC2 Expression in Malignant Tissues from Ovarian Cancer Patients,” J Natl Cancer Ins., Oct. 7; 84(19):1512-7 (1992).
Dabholkar, et al., “Messenger RNA Levels of XPAC and ERCC1 in Ovarian Cancer Tissue Correlate with Response to Platinum-Based Chemotherapy,” J Clin Invest., Aug.; 94(2): 703-8 (1994).
Dakhama, A., et al., “Amplification of Human β-Actin Gene by the Reverse Transcripase-Polymerase Chain Reaction: Implications for Assessment of RNA from Formalin-Fixed, Paraffin-Embedded Material,” J. Histochem. and Cytochem., vol. 44, No. 10, pp. 1205-1207 (1996).
Damia, et al., “Expression of Genes Involved in Nucleotide Excision Repair and Sensitivity to Cisplatin and Melphalan in Human Cancer Cell Lines,” Eur J Cancer, Oct.; 34(11): 1783-8 (1998).
de Andrés, B., et al., “Improved Method for mRNA Extraction from Paraffin-Embedded Tissues,” BioTechniques, vol. 18, No. 1, pp. 42-43 (1995).
Duin Van M, et al., “Molecular Characterization of the Human Excision Repair Gene ERCC-1: cDNA Cloning and Amino Acid Homology with the Yeast DNA Repair Gene Rad10,” Cell 44(6): pp. 913-923 (1986).
Eads, C. A., et al., “CpG Island Hypermethylation in Human Colorectal Tumors is Not Associated with DNA Methyltransferase Overexpression,” Cancer Research, vol. 59, pp. 2302-2306 (1999).
Edamoto, Y., et al., “Hepatitis C and B Virus Infections in Hepatocellular Carcinoma,” Cancer, vol. 77, No. 9, pp. 1787-1791 (1996).
Elder, et al., “Immunohistochemical Determination of Thymidylate Synthase in Colorectal Cancer-Methodological Studies,” European Journal of Cancer 33(13): pp. 2278-2281 (1997).
Elder, et al., “Thymidylate Synthase Expression in Colorectal Cancer: a Prognostic and Predictive Marker of Benefit from Adjuvant Fluorouracil-Based Chemotherapy,” Journal of Oncology 20(7): pp. 1721-1728 (2002).
Elder, et al., “Thymidylate Synthase Expression: an Independent Prognostic Factor for Local Recurrence, Distant Metastasis, Disease-Free and Overall Survival in Rectal Cancer,” Clinical Cancer Research, vol. 6, pp. 1378-1384 (2000).
Elder, et al.
Kenyon & Kenyon LLP
Response Genetics, Inc.
Yaen Christopher H
LandOfFree
Method of determining a chemotherapeutic regimen based on... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of determining a chemotherapeutic regimen based on..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of determining a chemotherapeutic regimen based on... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4185328